Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.
Need a custom stock scraper? Want to do some machine learning? We are here to help! Reach out to us!